0001209191-19-059174.txt : 20191204 0001209191-19-059174.hdr.sgml : 20191204 20191204190547 ACCESSION NUMBER: 0001209191-19-059174 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20191202 FILED AS OF DATE: 20191204 DATE AS OF CHANGE: 20191204 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: NORTHCOTT JOHN CENTRAL INDEX KEY: 0001615000 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 000-24006 FILM NUMBER: 191269192 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH STREET 2: C/O NEKTAR THERAPEUTICS CITY: SAN FRANCISCO STATE: CA ZIP: 94158 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: NEKTAR THERAPEUTICS CENTRAL INDEX KEY: 0000906709 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943134940 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 BUSINESS PHONE: 4154825300 MAIL ADDRESS: STREET 1: 455 MISSION BAY BOULEVARD SOUTH CITY: SAN FRANCISCO STATE: CA ZIP: 94158 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS INC DATE OF NAME CHANGE: 19980723 FORMER COMPANY: FORMER CONFORMED NAME: INHALE THERAPEUTIC SYSTEMS DATE OF NAME CHANGE: 19940303 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2019-12-02 0 0000906709 NEKTAR THERAPEUTICS NKTR 0001615000 NORTHCOTT JOHN C/O NEKTAR THERAPEUTICS 455 MISSION BAY BOULEVARD SOUTH SAN FRANCISCO CA 94185 0 1 0 0 SVP & Chief Commercial Officer Common Stock 2019-12-02 4 A 0 200000 0.00 A 200000 D Stock Option 19.48 2019-12-02 4 A 0 200000 0.00 A 2027-12-01 Common Stock 200000 200000 D The grant of Restricted Stock Units ("RSUs") will vest according to a four-year vesting schedule, with 25% vesting on February 15, 2021 and the remainder vesting over three years in equal quarterly installments. This option vests as to 25% of the shares subject to the option on the first anniversary of the grant date and the remaining 75% of the shares subject to the option vest in equal monthly installments over the three-year period thereafter, in each case based on the Reporting Person's continuous service to the issuer. Mark A. Wilson, Attorney-in-Fact 2019-12-04